SUPPLY of LUTATHERA® (lutetium Lu 177 dotatate) and PLUVICTO™ (lutetium Lu 177 vipivotide tetraxetan)
Award Notice Posted
- Solicitation number
- 12481254
- Agency
-
Defense Health Agency
Department of Defense
- Awarded
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- HT001426FE141
- NAICS code
- Not on record
- PSC
- Not on record
- Place of performance
- Bethesda, Maryland 20889, United States
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Health Agency awarded a sole-source contract to Novartis Pharmaceuticals Corporation on September 30, 2026, for supply of LUTATHERA® (lutetium Lu 177 dotatate) and PLUVICTO™ (lutetium Lu 177 vipivotide tetraxetan) for targeted radioligand therapy in the Nuclear Medicine Division of the Department of Radiology at Walter Reed National Military Medical Center.
Novartis is the sole source for PLUVICTO™. The contract number is HT001426FE141. No set-aside was used in this procurement.
Notice text
Clinical Utility: It is used for targeted radioligand therapy for specific types of prostate cancer within the Nuclear Medicine Division of the Department of Radiology at WRNMMC. Novartis Pharmaceuticals Corporation is the sole source for Pluvicto. Therefore, the recommended course of action is to award a contract directly to Novartis. This approach is deemed to be in the government's best interest to ensure the seamless delivery of these critical supplies and maintain continuity of patient care at WRNMMC. The acquisition will be treated as a sole-source procurement.
Awarded contract HT001426FE141 to Novartis Pharmaceuticals Corporation for 480119.64 on 2026-09-30.
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity